Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned
An EMA advisory committee has set back Takeda Pharmaceutical Co. Ltd.’s oncology plans by rejecting Ninlaro as a treatment for multiple myeloma in the region, saying supporting data was inadequate for its backing but the Japanese company aims to appeal the decision.
You may also be interested in...
A CHMP about turn on Takeda's Ninlaro (ixazomib) for multiple myeloma means the Japanese firm is back on track to compensate for lost revenues from the impending patent expiry of key product Velcade. However, the Japanese firm will have a tough time ensuring Ninlaro is not overshadowed by rivals.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.